– Keynote Speakers –
Dr. Bruno Gonzalez-Zorn is full Professor and Head of the Antimicrobial Resistance Unit (ARU) at the Complutense University in Madrid (Spain), a multidisciplinary laboratory he founded in 2004. His work, focused on the flux of antimicrobial resistance genes and bacteria between humans, animals and the environment, has brought One Health to the forefront of research on antimicrobial resistance. Gonzalez-Zorn gained his DVM in 1996 studying in Spain and Germany and his European PhD in 2001. After his Postdoc at the Pasteur Institute in Paris, he received a Ramón y Cajal tenure-track contract from the Spanish Ministry of Science to return to Spain. He has been awarded the National Microbiology Award by the Spanish Society for Microbiology in 2011, the National Antimicrobial Resistance Research Award for his research on mcr-1 and wastewater by the Ministry of Health in 2018, and the Award for antimicrobial resistance alternatives by the Veterinary Royal Academy in 2020. In 2011 he was elected the first non-clinical member of the Scientific Advisory Board of the JPI AMR, co-authoring the first One Health Strategic and Innovation Research Agendas (2014 and 2019). He is researcher at the Veterinary Health Surveillance Center (VISAVET) and former President of the Molecular Microbiology Group of the Spanish Society for Microbiology. Gonzalez-Zorn has led research projects on the ecology of antimicrobial resistance in the USA, Latin America, Africa and Asia. Gonzalez-Zorn works on the Spanish National Action Plan against Antimicrobial Resistance and has advised Governments worldwide in the implementation of the One Health approach in their own Action Plans. His work includes fundamental microbiological research and exploring global and clinical antimicrobial resistance paradigms, covering a transdisciplinary holistic One Health perspective.
Jesús Fortún. Head of Section of the Infectious Diseases Service of the Ramón y Cajal Hospital in Madrid. Clinical Professor at the University of Alcalá. He has chaired the SEIMC study groups on infection in transplant patients (GESITRA) and fungal infection (GEMICOMED). Coordinator and collaborator of the SEIMC guidelines on fungal infection, endovascular catheter-associated infection, cytomegalovirus infection in immunosuppressed patients, tuberculosis in transplant recipients and infection by large-negative bacilli multi-resistant in transplanted. He has been part of the expert panel of the guidelines of the European Society for Infectious Diseases and Clinical Microbiology (ESCMID) on aspergillosis and infections associated with biological drugs. Principal investigator of several projects in public and private calls. Active member of REIPI (National Research Network on Infectious Diseases) and CIBER on Infectious E. (CIBERINFEC). Author or co-author of more than 300 publications indexed in the web of Science. H-index (Hirsch) of 48.
Abelardo Margolles received his Ph.D. in Pharmacy at the University of Santiago de Compostela, Spain, in 1997. After a postdoctoral stay in the University of Groningen, in 2001 he became Staff Scientist of CSIC. Currently, he holds a Profesor de Investigación position in IPLA-CSIC. He has had the opportunity to carry out his research thanks to competitive grants funded by regional, national and international funding agencies, as well as several contracts with the industry. Since 2016 he is Scientific Founder of the start-up MicroViable Therapeutics. His present research interest focuses on technological and health applications of food and intestinal microbiomes, mechanistic studies of the health-promoting effects of food and intestinal bacteria, as well as the understanding of the molecular interactions between the gut microbiota and the host.